Skip to main content

Neuropathic Pain News

Degenerative Cervical Myelopathy Patients Often Have Severe Residual Paresthesia

MONDAY, March 11, 2024 – Just under half of patients (45 percent) with degenerative cervical myelopathy (DCM) show severe residual paresthesia one year after surgery, according to a study published...

High-Concentration Capsaicin Patch Can Cut Neuropathic Pain Intensity

WEDNESDAY, Feb. 7, 2024 – For patients with neuropathic pain, a high-concentration capsaicin patch (HCCP) is effective for reducing pain intensity, according to a study published online Feb. 7 in...

All Pain Is Not the Same When It Comes to MS

THURSDAY, Jan. 11, 2024 – Pain can present itself in many forms for people battling multiple sclerosis, and one type can interfere with exercising, new research shows. One class of pain experienced...

Pain Reduced With Target Muscle Reinnervation at Time of Amputation

WEDNESDAY, Jan. 10, 2024 – For patients undergoing amputation, targeted muscle reinnervation (TMR) at the time of amputation improves pain scores and reduces the rate of neuroma formation, according...

Averitas Pharma Announces FDA Approval of Qutenza for the Treatment of Neuropathic Pain Associated with Diabetic Peripheral Neuropathy of the Feet

AACHEN, Germany and MORRISTOWN, N.J., July 21, 2020 /PRNewswire/ – Grünenthal announced today that its U.S. subsidiary Averitas Pharma, Inc. received U.S. Food and Drug Administration (FDA) approval ...

FDA Approves Lyrica CR (pregabalin) Extended-Release Tablets for Neuropathic Pain Conditions

October 12, 2017 - Pfizer Inc. (NYSE: PFE) announced today that the United States Food and Drug Administration (FDA) has approved Lyrica CR (pregabalin) extended-release tablets CV as once-daily...

Ask a question

To post your own question to this support group, sign in or create an account.

Further information

Related condition support groups

Neuralgia

Related drug support groups

gabapentin, Lyrica, amitriptyline, pregabalin, doxepin, oxcarbazepine